B01AC13 • abciximab • Blood and blood forming organs | Antithrombotic agents | Platelet aggregation inhibitors excl. heparin
Abciximab is a medication used to prevent thrombotic complications during interventional cardiac procedures, such as coronary angioplasty. It is a glycoprotein IIb/IIIa receptor inhibitor that prevents platelet aggregation and blood clot formation.
This medication is administered intravenously and is primarily used in patients with acute coronary syndromes or those undergoing percutaneous coronary intervention (PCI). Abciximab is often combined with other antithrombotic agents, such as heparin or aspirin, to enhance treatment efficacy.
Side effects may include bleeding, thrombocytopenia (low platelet count), or allergic reactions. Therefore, patients must be closely monitored during administration. Its use is contraindicated in patients with a high risk of bleeding or a history of hemorrhagic stroke.
Abciximab is an effective medication for reducing the risk of thrombotic complications, but its use requires strict medical supervision.
Substance: abciximab
Date of last drug list: 01-12-2017
Commercial code: W08065001
Concentration: 2mg / ml
Pharmaceutical form: solution for injection / infusion
Quantity: 1
Product type: original
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.